Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02369900 · ClinicalTrials.gov registry record · Phase 2
Esmolol to Treat the Hemodynamic Effects of Septic Shock
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT02369900 is a Phase 2 study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 40 participants.
The verdict
NCT02369900, a Phase 2 study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the effects of controlling the heart rate of patients with septic shock using an intravenous medication called esmolol.
Interventions
- OTHER Saline
- DRUG Esmolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-03 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02369900
The ClinicalTrials.gov registry entry for NCT02369900 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT02369900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02369900 about?
NCT02369900 is a clinical study titled "Esmolol to Treat the Hemodynamic Effects of Septic Shock". The main purpose of this study is to determine the effects of controlling the heart rate of patients with septic shock using an intravenous medication called esmolol.
What is the current status of trial NCT02369900?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2015-03. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT02369900?
The interventions under investigation include: Saline (OTHER), Esmolol (DRUG).
Who is sponsoring clinical trial NCT02369900?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.